Prof. J. Eduardo Sousa

• 
  www.cordis.com/logc_common/layout/showPage.jsp?article_ - [Cached Version]
  Published on: 11/13/2001    Last Visited: 3/31/2004  

  "We recently reported data from the RAVEL* clinical study showing virtually no late loss and zero restenosis in previously untreated, or de novo, lesions six months following placement of the CYPHER Sirolimus-eluting Stent," said Prof. J. Eduardo Sousa, M.D., Ph.D., Co-principal Investigator, and Professor of Interventional Cardiology at Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil."Now we have evidence this stent may show a similar effect in preventing reblockages in previously stented arteries," he said.
  
  According to Dr. Sousa, results from the study indicate extremely low in-stent late loss (0.08 mm in minimum lumen diameter) at four-month follow-up in the 25 ISR patients treated at his hospital centre.
  ...
  "We were particularly impressed by the efficacy of the CYPHER Sirolimus-eluting Stent against a wide variety of restenotic lesions," said Dr. Sousa.

• 
  AHA News Releases - [Cached Version]
  Published on: 10/15/2000    Last Visited: 6/14/2001  

  Many approaches to reduce restenosis have failed , but we believed delivering medication directly to the site of artery damage would be a rational approach , says J. Eduardo Sousa , M.D. , Ph.D. , lead author of the study and director of the Institute Dante Pazzanese of Cardiology in Sao Paulo , Brazil.We focused on stents because they act as permanent scaffolding within the artery..
  
  Thirty patients with chest pain ( angina ) were evenly divided into two groups receiving either a slow-release or fast-release formulation of sirolimus-coated stents.Twenty six of the total group had stable angina , while four had unstable chest pain.About 63 percent of subjects were men.The average age of the group receiving slow release was 58 and the average age of the other group was 55.
  ...
  That's too low to cause any re-narrowing , explains Sousa.
  
  In addition , no patients had died , suffered a heart attack , developed blood clots or needed repeat procedures.
  
  Unlike the combined use of stents and radiation , the drug-coated stent also slowed edge restenosis and blood clot formation ( thrombosis ).
  
  There appeared to be no difference in the two drug formulations.
  
  ...
  This approach is fast , easy and predictable without major side effects , says Sousa.Interventional cardiologists are implanting stents everyday.They wouldn't have to change the way they work in the cardiac catheterization lab.This could be a milestone in interventional cardiology..
  
  The authors say the results warrant further confirmation by large , placebo controlled multicenter trials.

• 
  American Heart Association - [Cached Version]
  Published on: 1/14/2002    Last Visited: 10/9/2002  

  J. Eduardo Sousa, MDInstitute Dante Pazzanese of Cardiology

• 
  Boston Globe Online / Nation | World / New angioplasty... - [Cached Version]
  Published on: 3/18/2002    Last Visited: 3/18/2002  

  Dr. J. Eduardo Sousa of the Dante Pazzanese Institute of Cardiology in Sao Paulo presented two years of follow-up with those 43 initial patients.While three of them have needed heart procedures for worsening disease in other parts of their hearts, all of the areas treated with the Cordis stents are flowing freely.
  
  Sousa projected an X-ray of the heart of one of the patients, showing a wide, obstruction-free artery."No lesion.No problem," he said."The artery is completely open after two years' follow-up."

• 
  CXVascular - Cardiovascular News - Cardiovascular News, - [Cached Version]
  Published on: 12/12/2004    Last Visited: 2/21/2006  

  Presenting the four-year results, Dr J Eduardo Sousa, of the Dante Pazzanese Institute, Sao Paulo, Brazil, revealed that patients who received the Cypher Stent continued to experience event-free survival rates compared to the bare metal stent (BMS) control arm.

• 
  CardioValens.com:Matters of the Heart - [Cached Version]
  Published on: 8/4/2003    Last Visited: 4/21/2005  

  "These data reveal that the absence of restenosis we saw at 4-month followup in 30 patients (includes first 15-patient group) treated with this device in Sao Paulo is sustained at one year," said Prof. J. Eduardo Sousa, M.D., Principal Investigator, and Professor of Interventional Cardiology at Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil.
  ...
  For more than two decades, Professors Sousa and Serruys have been recognized as international leaders in the field of angioplasty and stenting.
  ...
  Dr. Sousa noted follow-up quantitative coronary angiography and 3-D IVUS (intravascular ultra-sound) assessment in Sao Paulo of the 30 patients at four months and now in the first group of 15 patients at 12 months by independent core laboratories revealed good coverage of the stents with endothelium (layer of cells lining vessel walls and the heart) and no evidence of in-stent or edge restenosis.
  
  In clinical follow-up, there also have been no adverse events from this treatment.

• 
  Cardiology Advance Is Hailed - [Cached Version]
  Published on: 3/18/2002    Last Visited: 3/18/2002  

  Dr. J. Eduardo Sousa of the Dante Pazzanese Institute of Cardiology in Sao Paulo, Brazil, presented two years of follow-up with those 43 initial patients.All of the areas treated with the Cordis stents are flowing freely.

• 
  Cardiology Breakthrough - [Cached Version]
  Published on: 7/1/2003    Last Visited: 8/3/2008  

  The results continue to hold with 93.3 percent event-free survival," says Prof. J. Eduardo Sousa, Professor of Interventional Cardiology, Dante Pazzanes Institute, Sao Paulo, Brazil.

• 
  Cath Lab Digest - [Cached Version]
  Published on: 1/1/2002    Last Visited: 6/30/2005  

  "We recently reported data from the RAVEL clinical study showing virtually no late loss and zero restenosis in previously untreated, or de novo, lesions six months following placement of the CYPHER Sirolimus-eluting Stent," said Prof. J. Eduardo Sousa, M.D., Ph.D., Co-principal Investigator, and Professor of Interventional Cardiology at Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil."Now we have evidence this stent may show a similar effect in preventing reblockages in previously stented arteries," he said.According to Dr. Sousa, results from the study indicate extremely low in-stent late loss (0.08 mm in minimum lumen diameter) at four-month follow-up in the 25 ISR patients treated at his hospital center.In-stent late loss is a sensitive and specific measure of the amount of tissue proliferation that can result in reblockage of the vessel.Additionally, the study's results show 0.0% restenosis, 0.0% TLR (target lesion revascularization), no thrombosis, and no deaths.The reference vessel diameter was 2.8 mm, with a mean diameter stenosis of 7.7%.Results were documented using intravenous ultrasound (IVUS) and quantitative coronary angiography evaluated by independent Core Laboratories."We were particularly impressed by the efficacy of the CYPHER Sirolimus-eluting Stent against a wide variety of restenotic lesions," said Dr. Sousa.
  
  Cell Transplants Used to Repair Heart Muscle Damage

• 
  Cordis' CYPHER™ Sirolimus-eluting Stent Shows Promise... - [Cached Version]
  Published on: 12/21/2001    Last Visited: 12/23/2001  

  "We recently reported data from the RAVEL* clinical study showing virtually no late loss and zero restenosis in previously untreated, or de novo, lesions six months following placement of the CYPHER Sirolimus-eluting Stent," said Prof. J. Eduardo Sousa, M.D., Ph.D., co-principal investigator, and professor of interventional cardiology at Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil."Now we have evidence this stent may show a similar effect in preventing reblockages in previously stented arteries," he said.
  
  According to Dr. Sousa, results from the study indicate extremely low in-stent late loss (0.08 mm in minimum lumen diameter) at four-month follow-up in the 25 ISR patients treated at his hospital center.In-stent late loss is a sensitive and specific measure of the amount of tissue proliferation that can result in reblockage of the vessel.
  
  Additionally, the study's results show 0.0 percent restenosis, 0.0 percent TLR (target lesion revascularization), no thrombosis and no deaths.The reference vessel diameter was 2.8 mm, with a mean diameter stenosis of 7.7 percent.Results were documented using intravenous ultrasound (IVUS) and quantitative coronary angiography evaluated by independent Core Laboratories.
  
  ...
  "We were particularly impressed by the efficacy of the CYPHER Sirolimus-eluting Stent against a wide variety of restenotic lesions," said Dr. Sousa.

Page:  1 2 3 4